Abcam plc (NASDAQ:ABCM – Get Rating) shares gapped down before the market opened on Tuesday . The stock had previously closed at $16.19, but opened at $15.47. Abcam shares last traded at $15.32, with a volume of 2,585 shares.
Analysts Set New Price Targets
ABCM has been the subject of several analyst reports. Royal Bank of Canada boosted their target price on Abcam from GBX 1,700 ($20.10) to GBX 2,200 ($26.01) in a research note on Wednesday, September 14th. Panmure Gordon raised Abcam from a “hold” rating to a “buy” rating in a research note on Monday, September 5th.
Abcam Trading Up 2.1 %
The stock has a fifty day simple moving average of $15.51 and a 200-day simple moving average of $14.92.
Institutional Trading of Abcam
Abcam Company Profile
Abcam plc, a life science company, focuses on identifying, developing, and distributing reagents and tools for scientific research, diagnostics, and drug discovery. Its principal products include primary and secondary antibodies; conjugated antibodies and conjugation kits; singleplex and multiplex immunoassays; proteins and peptides that include cytokines; edited cell lines and lysates; and various other products, including cellular activity kits, miRNA kits, biochemicals, and cell signaling pathway tools.
- Get a free copy of the StockNews.com research report on Abcam (ABCM)
- Salesforce Cuts Labor, Shows Strong Earnings Despite Challenges
- Microsoft Shares: Is it Time to Back Up the Truck?
- Institutional Support for Analog Devices Remains High
- Is the 60/40 Portfolio Mix Still in Vogue?
- Three CBD Stocks to Dominate a Budding Industry
Receive News & Ratings for Abcam Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abcam and related companies with MarketBeat.com's FREE daily email newsletter.